IL6 and parasitic infectious disease: Similar results were obtained in terms of parasitemia (Group 1, Supplementary Figure S4B) and survival (Group 1, Supplementary Figure S4C) as in the mice challenged 30 days after the second IL-6 Tg-PbANKA/LISP2 infection, shown in Figure 6, with a sterile protection against a challenge with WT PbANKA SPZ in a homologous prime/boost immunization regimen (Group 1, Supplementary Figure S4A).